142 related articles for article (PubMed ID: 7594533)
1. Regulation of JAK3 expression and activation in human B cells and B cell malignancies.
Tortolani PJ; Lal BK; Riva A; Johnston JA; Chen YQ; Reaman GH; Beckwith M; Longo D; Ortaldo JR; Bhatia K; McGrath I; Kehrl J; Tuscano J; McVicar DW; O'Shea JJ
J Immunol; 1995 Dec; 155(11):5220-6. PubMed ID: 7594533
[TBL] [Abstract][Full Text] [Related]
2. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.
Liu KD; Gaffen SL; Goldsmith MA; Greene WC
Curr Biol; 1997 Nov; 7(11):817-26. PubMed ID: 9382798
[TBL] [Abstract][Full Text] [Related]
3. IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling.
Murata T; Noguchi PD; Puri RK
J Immunol; 1996 Apr; 156(8):2972-8. PubMed ID: 8609418
[TBL] [Abstract][Full Text] [Related]
4. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain.
Kirken RA; Rui H; Malabarba MG; Howard OM; Kawamura M; O'Shea JJ; Farrar WL
Cytokine; 1995 Oct; 7(7):689-700. PubMed ID: 8580378
[TBL] [Abstract][Full Text] [Related]
5. CD40-mediated regulation of interleukin-4 signaling pathways in B lymphocytes.
Siepmann K; Wohlleben G; Gray D
Eur J Immunol; 1996 Jul; 26(7):1544-52. PubMed ID: 8766559
[TBL] [Abstract][Full Text] [Related]
6. Impaired IL-7 signaling may explain a case of atypical JAK3-SCID.
Li J; Nara H; Rahman M; Juliana FM; Araki A; Asao H
Cytokine; 2010 Feb; 49(2):221-8. PubMed ID: 19889552
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of IL-4 and IL-13 on CD44 expression in the Burkitt's lymphoma B cell line BL30/B95-8 and in Epstein-Barr virus (EBV) transformed human B cells: loss of IL-13 receptors on Burkitt's lymphoma B cells.
Gee K; Kozlowski M; Kryworuchko M; Diaz-Mitoma F; Kumar A
Cell Immunol; 2001 Aug; 211(2):131-42. PubMed ID: 11591117
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells.
Marzec M; Halasa K; Kasprzycka M; Wysocka M; Liu X; Tobias JW; Baldwin D; Zhang Q; Odum N; Rook AH; Wasik MA
Cancer Res; 2008 Feb; 68(4):1083-91. PubMed ID: 18281483
[TBL] [Abstract][Full Text] [Related]
9. Human activation-induced cytidine deaminase is induced by IL-4 and negatively regulated by CD45: implication of CD45 as a Janus kinase phosphatase in antibody diversification.
Zhou C; Saxon A; Zhang K
J Immunol; 2003 Feb; 170(4):1887-93. PubMed ID: 12574355
[TBL] [Abstract][Full Text] [Related]
10. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas.
Kolenko V; Wang Q; Riedy MC; O'Shea J; Ritz J; Cathcart MK; Rayman P; Tubbs R; Edinger M; Novick A; Bukowski R; Finke J
J Immunol; 1997 Sep; 159(6):3057-67. PubMed ID: 9300731
[TBL] [Abstract][Full Text] [Related]
11. Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases.
Cetkovic-Cvrlje M; Uckun FM
Arch Immunol Ther Exp (Warsz); 2004; 52(2):69-82. PubMed ID: 15179321
[TBL] [Abstract][Full Text] [Related]
12. Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery.
Witthuhn BA; Williams MD; Kerawalla H; Uckun FM
Leuk Lymphoma; 1999 Jan; 32(3-4):289-97. PubMed ID: 10037026
[TBL] [Abstract][Full Text] [Related]
13. Activation of JAK3, but not JAK1, is critical to interleukin-4 (IL4) stimulated proliferation and requires a membrane-proximal region of IL4 receptor alpha.
Malabarba MG; Kirken RA; Rui H; Koettnitz K; Kawamura M; O'Shea JJ; Kalthoff FS; Farrar WL
J Biol Chem; 1995 Apr; 270(16):9630-7. PubMed ID: 7721895
[TBL] [Abstract][Full Text] [Related]
14. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
Wang LH; Kirken RA; Erwin RA; Yu CR; Farrar WL
J Immunol; 1999 Apr; 162(7):3897-904. PubMed ID: 10201908
[TBL] [Abstract][Full Text] [Related]
15. Regulation of JAK3 expression in human monocytes: phosphorylation in response to interleukins 2, 4, and 7.
Musso T; Johnston JA; Linnekin D; Varesio L; Rowe TK; O'Shea JJ; McVicar DW
J Exp Med; 1995 Apr; 181(4):1425-31. PubMed ID: 7535338
[TBL] [Abstract][Full Text] [Related]
16. Jak3 activation in human lymphocyte precursor cells.
Sharfe N; Dadi HK; O'Shea JJ; Roifman CM
Clin Exp Immunol; 1997 Jun; 108(3):552-6. PubMed ID: 9182906
[TBL] [Abstract][Full Text] [Related]
17. Similarities and differences in signal transduction by interleukin 4 and interleukin 13: analysis of Janus kinase activation.
Keegan AD; Johnston JA; Tortolani PJ; McReynolds LJ; Kinzer C; O'Shea JJ; Paul WE
Proc Natl Acad Sci U S A; 1995 Aug; 92(17):7681-5. PubMed ID: 7544000
[TBL] [Abstract][Full Text] [Related]
18. Defective lymphoid development in mice lacking Jak3.
Nosaka T; van Deursen JM; Tripp RA; Thierfelder WE; Witthuhn BA; McMickle AP; Doherty PC; Grosveld GC; Ihle JN
Science; 1995 Nov; 270(5237):800-2. PubMed ID: 7481769
[TBL] [Abstract][Full Text] [Related]
19. JAK3 protein tyrosine kinase mediates interleukin-7-induced activation of phosphatidylinositol-3' kinase.
Sharfe N; Dadi HK; Roifman CM
Blood; 1995 Sep; 86(6):2077-85. PubMed ID: 7662955
[TBL] [Abstract][Full Text] [Related]
20. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits.
Miyazaki T; Kawahara A; Fujii H; Nakagawa Y; Minami Y; Liu ZJ; Oishi I; Silvennoinen O; Witthuhn BA; Ihle JN
Science; 1994 Nov; 266(5187):1045-7. PubMed ID: 7973659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
